| Medical and Health Sciences | Lifetime | 569 | US 306 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 20 | US 11 | 99.99 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 34 | US 16 | 99.88 |
| Nephrology | Lifetime | 32 | US 19 | 99.75 |
| Cardiology and Cardiovascular Medicine | Lifetime | 351 | US 201 | 99.54 |
| Clinical Biochemistry | Lifetime | 564 | US 245 | 88.76 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 4 | US 2 | 99.98 |
| Nephrology | 2021-2025 | 35 | US 14 | 99.10 |
| Medical Physiology | 2021-2025 | 128 | US 44 | 98.54 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 171 | US 85 | 99.07 |
| Surgery | 2021-2025 | 378 | US 150 | 97.22 |
| Molecular Biology | 2021-2025 | 912 | US 256 | 94.88 |
| Clinical Pharmacology | 2021-2025 | 388 | US 112 | 82.50 |
| Genetics | 2021-2025 | 677 | US 253 | 79.49 |
| Chronic Kidney Disease and Diabetes | Lifetime | 15 | US 11 | 99.83 |
| Diabetes Treatment and Management | Lifetime | 27 | US 15 | 99.84 |
| Hormonal Regulation and Hypertension | Lifetime | 40 | US 21 | 99.64 |
| Blood Pressure and Hypertension Studies | Lifetime | 53 | US 26 | 99.75 |
| Diabetes Management and Research | Lifetime | 54 | US 30 | 99.69 |
| Diet and metabolism studies | Lifetime | 209 | US 89 | 99.52 |
| Advanced Glycation End Products research | Lifetime | 50 | US 23 | 98.93 |
| Renal Diseases and Glomerulopathies | Lifetime | 158 | US 66 | 98.96 |
| Metabolism, Diabetes, and Cancer | Lifetime | 240 | US 105 | 98.96 |
| Cardiovascular Function and Risk Factors | Lifetime | 465 | US 257 | 99.16 |
| Pancreatic function and diabetes | Lifetime | 378 | US 173 | 98.84 |
| Cardiovascular Health and Disease Prevention | Lifetime | 251 | US 114 | 98.68 |
| Diabetes and associated disorders | Lifetime | 432 | US 176 | 98.22 |
| Pharmacology and Obesity Treatment | Lifetime | 184 | US 84 | 97.78 |
| Dialysis and Renal Disease Management | Lifetime | 431 | US 174 | 98.04 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 536 | US 229 | 98.27 |
| Apelin-related biomedical research | Lifetime | 132 | US 49 | 95.94 |
| Electrolyte and hormonal disorders | Lifetime | 370 | US 169 | 96.63 |
| Renin-Angiotensin System Studies | Lifetime | 601 | US 242 | 94.97 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 885 | US 379 | 91.35 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 911 | US 250 | 87.44 |
| Potassium and Related Disorders | Lifetime | 738 | US 343 | 87.87 |
| GDF15 and Related Biomarkers | Lifetime | 554 | US 176 | 80.97 |
| Diet and metabolism studies | 2021-2025 | 2 | US 1 | 99.92 |
| Hormonal Regulation and Hypertension | 2021-2025 | 1 | US 1 | 99.94 |
| Diabetes Treatment and Management | 2021-2025 | 6 | US 5 | 99.95 |
| Diabetes Management and Research | 2021-2025 | 7 | US 5 | 99.85 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 7 | US 4 | 99.70 |
| Pancreatic function and diabetes | 2021-2025 | 13 | US 7 | 99.58 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 9 | US 6 | 99.66 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 19 | US 7 | 99.54 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 190 | US 90 | 98.59 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 27 | US 21 | 95.95 |
| Pharmacology and Obesity Treatment | 2021-2025 | 30 | US 16 | 97.30 |
| Electrolyte and hormonal disorders | 2021-2025 | 32 | US 10 | 96.14 |
| Diabetes and associated disorders | 2021-2025 | 218 | US 95 | 95.02 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 345 | US 103 | 93.15 |
| Diet, Metabolism, and Disease | 2021-2025 | 399 | US 79 | 90.23 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 639 | US 172 | 89.22 |
| Apelin-related biomedical research | 2021-2025 | 74 | US 13 | 80.77 |
| Renal function and acid-base balance | 2021-2025 | 149 | US 49 | 80.88 |
| Potassium and Related Disorders | 2021-2025 | 202 | US 80 | 82.79 |
| Clinical practice guidelines implementation | 2021-2025 | 613 | US 117 | 73.03 |
| Adrenal Hormones and Disorders | 2021-2025 | 693 | US 95 | 70.05 |
| Neurological and metabolic disorders | 2021-2025 | 287 | US 64 | 66.00 |
| Ion Transport and Channel Regulation | 2021-2025 | 563 | US 179 | 59.75 |
| Sphingolipid Metabolism and Signaling | 2021-2025 | 697 | US 187 | 59.36 |